Compare JPMorgan Chase & Co (JPM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Repligen Corporation Common Stock — how do they compare? JPMorgan Chase & Co trades at $338.38 (market cap $890.37B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: JPMorgan Chase & Co is far larger — about 78.7× Repligen Corporation Common Stock's market cap, and JPMorgan Chase & Co pays a 1.97% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Repligen Corporation Common Stock for 0 Days on average.
| JPM | RGEN | |
|---|---|---|
Market Cap | $890.37B | $11.31B |
Volume | 10,236,412 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $365.18 | $194.57 |
52-Week Low | $282.84 | $102.87 |
Typical Hold Time | 127 Days | 0 Days |
Enterprise Value | $1.40T | $11.20B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $331.43, down 0.86% on the day, with a bearish technical signal despite strong fundamentals. The company reported mixed Q3 2026 earnings but beat expectations in Q1 and Q2, with revenue growing to $181.85B in 2025. Analyst consensus remains positive with a $373.36 price target, though technical indicators show resistance near $336-339 levels.
JPMorgan offers solid investment potential with strong profitability (33.38% net margin) and attractive valuation (P/E 13.9), but faces headwinds from negative cash flow trends and geopolitical risks highlighted in recent CEO warnings. The stock's current technical weakness suggests near-term consolidation before potential upside toward analyst targets.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
